Login to Your Account

Drug Draws U.S. Patients To China

Analyst: Gene Therapy Holds Promise, Despite Trial Death

By Randall Osborne

Monday, August 13, 2007
July's death of a patient in Targeted Genetics Inc.'s halted Phase I/II trial of the arthritis drug tgAAC94 shone the spotlight - unfavorably, again - on gene therapy, dragging all involved companies out for inspection. And it gave many investors an excuse to talk about China, as if many in biotech weren't already. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription